Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation
BackgroundCachexia is a leading cause of death among individuals with advanced cancer, yet effective pharmacological treatments are lacking. In this single-center retrospective study, we aimed to investigate the efficacy and safety of tocilizumab for the treatment of cancer cachexia accompanied by s...
Saved in:
| Main Authors: | Ping Chen, Dingyi Wang, Zhouwei Zhan, Ling Chen, Yu Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1477310/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
by: Sibel BOLUKÇU, et al.
Published: (2021-01-01) -
A spectacular effect of tocilizumab in Takayasu arteritis
by: Fatma Saïd, et al.
Published: (2024-11-01) -
Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids
by: Somayeh Sadeghi, et al.
Published: (2024-10-01) -
Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report
by: Yushi Cai, et al.
Published: (2025-04-01) -
Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
by: Nastaran Injinari, et al.
Published: (2024-10-01)